@venturebeat.com 6 years ago
Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018
@venturebeat.com 6 years ago
Augmenix to Unveil New Clinical Data on its Innovative Absorbable Hydrogel Technology at the 59th Annual Meeting of the American Society for Radiation Oncology
@venturebeat.com 6 years ago
NICE Announces Interventional Procedure Guidance Supporting Use of Hydrogel Spacer in Treatment of Prostate Cancer in the UK
@venturebeat.com 6 years ago
Augmenix, Inc. Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR® Hydrogel
@venturebeat.com 6 years ago
Augmenix Announces First Prostate Cancer Patients Treated with SpaceOAR® Hydrogel in Israel
@venturebeat.com 6 years ago
Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in New Zealand
@venturebeat.com 6 years ago
Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in Canada
@venturebeat.com 7 years ago
Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment
@venturebeat.com 7 years ago
Augmenix Announces Positive Three-Year Long-Term Data Highlighting Benefits of SpaceOAR® Hydrogel Spacer for Patients with Prostate Cancer